Chu Arthur J
MRC, Shantou University, Shantou, Guangdong, 515063, PR China.
Front Biosci. 2006 Jan 1;11:256-71. doi: 10.2741/1796.
Tissue factor (TF) plays a role in thrombogenesis. TF initiates blood coagulation resulting in the generation of protease coagulant mediators (FVIIa, FXa, and FIIa) and fibrin production. TF hypercoagulablility directly contributes to thrombus formation resulting from the major events of fibrin deposition and FIIa-induced platelet activation/aggregation. In addition, blood coagulation indirectly promotes thrombogenicity via the coagulation-inflammation cycle in which TF plays a diverging and converging role. As the consequence of coagulation-dependent inflammation in which protease-activated receptor (PAR) mediates the coagulant signaling to elicit cytokines, selectins, and growth factors, such inflammation facilitates thrombosis by platelet aggregation and leukocyte recruitment. As TF hypercoagulability concerned, anti-thrombotic strategies involve the prevention by anticoagulation and PAR antagonism. Anticoagulants block the direct and indirect thrombotic contributions, while PAR antagonists arrest coagulation-dependent inflammation. With respect to both thrombosis and inflammation being cardiovascular risk factors, such strategies offer diverse benefits to cardioprotection.
组织因子(TF)在血栓形成过程中发挥作用。TF启动血液凝固,导致蛋白酶凝血介质(FVIIa、FXa和FIIa)的产生以及纤维蛋白的生成。TF高凝状态直接导致血栓形成,这是由纤维蛋白沉积和FIIa诱导的血小板活化/聚集等主要事件引起的。此外,血液凝固通过凝血-炎症循环间接促进血栓形成,其中TF起着分散和汇聚的作用。作为凝血依赖性炎症的结果,蛋白酶激活受体(PAR)介导凝血信号以引发细胞因子、选择素和生长因子,这种炎症通过血小板聚集和白细胞募集促进血栓形成。就TF高凝状态而言,抗血栓策略包括抗凝预防和PAR拮抗。抗凝剂可阻断直接和间接的血栓形成作用,而PAR拮抗剂可阻止凝血依赖性炎症。鉴于血栓形成和炎症均为心血管危险因素,此类策略为心脏保护带来多种益处。